Moon­Lake’s stock falls more than 20% de­spite mid-stage suc­cess in pso­ri­at­ic arthri­tis

Moon­Lake Im­munother­a­peu­tics’ nanobody can­di­date tri­umphed in a mid-stage pso­ri­at­ic arthri­tis tri­al fol­low­ing past suc­cess­es in hidradeni­tis sup­pu­ra­ti­va and pso­ri­a­sis, but its shares plunged amid high­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER